A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model

Nipah virus: Virus-like particles protect against major public health concern A vaccine candidate consisting of virus-like particles could offer the first effective prophylaxis against the deadly Nipah virus. Endemic to Malaysia, Bangladesh, and India, Nipah virus is contracted from infected fruit b...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pramila Walpita, Yu Cong, Peter B. Jahrling, Oscar Rojas, Elena Postnikova, Shuiqing Yu, Lisa Johns, Michael. R. Holbrook
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c73ddbefeb8a401ca3556c3aba293d75
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c73ddbefeb8a401ca3556c3aba293d75
record_format	dspace
spelling	oai:doaj.org-article:c73ddbefeb8a401ca3556c3aba293d752021-12-02T12:30:10ZA VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model10.1038/s41541-017-0023-72059-0105https://doaj.org/article/c73ddbefeb8a401ca3556c3aba293d752017-08-01T00:00:00Zhttps://doi.org/10.1038/s41541-017-0023-7https://doaj.org/toc/2059-0105Nipah virus: Virus-like particles protect against major public health concern A vaccine candidate consisting of virus-like particles could offer the first effective prophylaxis against the deadly Nipah virus. Endemic to Malaysia, Bangladesh, and India, Nipah virus is contracted from infected fruit bats and causes severe inflammation of the brain. Pramila Walpita, of the University of Hawaii, working with colleagues at the United States’ National Institute of Allergy and Infectious Diseases, developed an effective vaccine of immunity-generating Nipah virus surface proteins without the virus’ disease-causing genetic material. Their vaccine elicited a significant protective antibody response, with 100% of vaccinated animals surviving subsequent Nipah virus infection. Despite its prevalence and lethality, Nipah virus has no licensed vaccine and poses a serious problem to the developing countries it affects. Walpita’s vaccine candidate could offer a much-needed treatment option and warrants further investigation and pre-clinical trials.Pramila WalpitaYu CongPeter B. JahrlingOscar RojasElena PostnikovaShuiqing YuLisa JohnsMichael. R. HolbrookNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 2, Iss 1, Pp 1-9 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Pramila Walpita Yu Cong Peter B. Jahrling Oscar Rojas Elena Postnikova Shuiqing Yu Lisa Johns Michael. R. Holbrook A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model
description	Nipah virus: Virus-like particles protect against major public health concern A vaccine candidate consisting of virus-like particles could offer the first effective prophylaxis against the deadly Nipah virus. Endemic to Malaysia, Bangladesh, and India, Nipah virus is contracted from infected fruit bats and causes severe inflammation of the brain. Pramila Walpita, of the University of Hawaii, working with colleagues at the United States’ National Institute of Allergy and Infectious Diseases, developed an effective vaccine of immunity-generating Nipah virus surface proteins without the virus’ disease-causing genetic material. Their vaccine elicited a significant protective antibody response, with 100% of vaccinated animals surviving subsequent Nipah virus infection. Despite its prevalence and lethality, Nipah virus has no licensed vaccine and poses a serious problem to the developing countries it affects. Walpita’s vaccine candidate could offer a much-needed treatment option and warrants further investigation and pre-clinical trials.
format	article
author	Pramila Walpita Yu Cong Peter B. Jahrling Oscar Rojas Elena Postnikova Shuiqing Yu Lisa Johns Michael. R. Holbrook
author_facet	Pramila Walpita Yu Cong Peter B. Jahrling Oscar Rojas Elena Postnikova Shuiqing Yu Lisa Johns Michael. R. Holbrook
author_sort	Pramila Walpita
title	A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model
title_short	A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model
title_full	A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model
title_fullStr	A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model
title_full_unstemmed	A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model
title_sort	vlp-based vaccine provides complete protection against nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/c73ddbefeb8a401ca3556c3aba293d75
work_keys_str_mv	AT pramilawalpita avlpbasedvaccineprovidescompleteprotectionagainstnipahviruschallengefollowingmultipledoseorsingledosevaccinationschedulesinahamstermodel AT yucong avlpbasedvaccineprovidescompleteprotectionagainstnipahviruschallengefollowingmultipledoseorsingledosevaccinationschedulesinahamstermodel AT peterbjahrling avlpbasedvaccineprovidescompleteprotectionagainstnipahviruschallengefollowingmultipledoseorsingledosevaccinationschedulesinahamstermodel AT oscarrojas avlpbasedvaccineprovidescompleteprotectionagainstnipahviruschallengefollowingmultipledoseorsingledosevaccinationschedulesinahamstermodel AT elenapostnikova avlpbasedvaccineprovidescompleteprotectionagainstnipahviruschallengefollowingmultipledoseorsingledosevaccinationschedulesinahamstermodel AT shuiqingyu avlpbasedvaccineprovidescompleteprotectionagainstnipahviruschallengefollowingmultipledoseorsingledosevaccinationschedulesinahamstermodel AT lisajohns avlpbasedvaccineprovidescompleteprotectionagainstnipahviruschallengefollowingmultipledoseorsingledosevaccinationschedulesinahamstermodel AT michaelrholbrook avlpbasedvaccineprovidescompleteprotectionagainstnipahviruschallengefollowingmultipledoseorsingledosevaccinationschedulesinahamstermodel AT pramilawalpita vlpbasedvaccineprovidescompleteprotectionagainstnipahviruschallengefollowingmultipledoseorsingledosevaccinationschedulesinahamstermodel AT yucong vlpbasedvaccineprovidescompleteprotectionagainstnipahviruschallengefollowingmultipledoseorsingledosevaccinationschedulesinahamstermodel AT peterbjahrling vlpbasedvaccineprovidescompleteprotectionagainstnipahviruschallengefollowingmultipledoseorsingledosevaccinationschedulesinahamstermodel AT oscarrojas vlpbasedvaccineprovidescompleteprotectionagainstnipahviruschallengefollowingmultipledoseorsingledosevaccinationschedulesinahamstermodel AT elenapostnikova vlpbasedvaccineprovidescompleteprotectionagainstnipahviruschallengefollowingmultipledoseorsingledosevaccinationschedulesinahamstermodel AT shuiqingyu vlpbasedvaccineprovidescompleteprotectionagainstnipahviruschallengefollowingmultipledoseorsingledosevaccinationschedulesinahamstermodel AT lisajohns vlpbasedvaccineprovidescompleteprotectionagainstnipahviruschallengefollowingmultipledoseorsingledosevaccinationschedulesinahamstermodel AT michaelrholbrook vlpbasedvaccineprovidescompleteprotectionagainstnipahviruschallengefollowingmultipledoseorsingledosevaccinationschedulesinahamstermodel
_version_	1718394424641191936

A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model

Ejemplares similares